 |
 |
 |
 |
 |
 |
 |
Member Information
George E. Woody, MD
Professor, Department of Psychiatry, School of Medicine
Office Phone: 215-399-0980 X112
Office Fax:
Email: woody@tresearch.org
Website(s):
Education: MD 1964, Temple University School of Medicine
Keywords: Addiction Psychiatry; Treatment Outcome; HIV risk reduction
Research and/or Clinical Interests:
Treatment outcome for persons with substance use disorders and its relationship to HIV risk reduction.
Summary:
Immediate plans are to continue projects that include 1) the Delaware Valley Node of the Clinical Trials Network (CTN) on which I am P.I. and responsible for 4 protocols: buprenorphine/naloxone for opioid dependent patients aged 14-21, motivational enhancement therapy, motivational incentives, and changes in treatment practices as a result of CTN participation; 2) publishing results of studies on the long term course of HIV risk behavior among persons in and out of methadone treatment and the effect of methadone on immune function; 3) studies of patients who dropped out or were suspended from methadone treatment and of "Seeking Safety", a group therapy for veterans with substance use disorders and PTSD; and 4) studies in Russia comparing naltrexone with or without fluoxetine for relapse prevention and HIV risk reduction, and of co-morbidities between HIV, hepatitis B and C, TB and alcohol and drug dependence. Long term plans are to 1) submit a competing renewal of CTN studies in the Fall of '03; 2) implement a study of depot vs oral naltrexone in Russia; 3) help investigators in Russia and Brazil write proposals for Centers of HIV prevention, treatment and research; and 4) submit a pilot study of buprenorphine for heroin addiction treatment of HIV+ and HIV- patients in Ukraine. This work will be done at the University of Pennsylvania/Philadelphia VAMC Addiction Treatment Research Center , the Treatment Research Institute, and the Penn Center for AIDS Research where I have been an active participant since their beginnings.
Representative Publications:
Forman, R., Bovasso, G., Woody, G., McNicholas, L., Clark, C. Royer-Malvestuto, C, Weinstein, S. Staff beliefs about drug abuse clinical trials. J. Substance Abuse Treatment. 23; 55-60, 2002.
Mercer, D.E., Woody, G.E. Psychotherapie bei Kokainabhangigkeit. Suchttherapie. 3:13-17, 2002.
Carroll, K.M., Farentinor, C., Ball , S.A. , Crits-Christoph, P., Libby, B., Morgenstern, J., Obert, J.L., Polcin, D., Woody, G.E. MET meets the real world: design issues and clinical strategies in the Clinical Trials Network. J. Substance Abuse Treatment. 23; 73-80, 2002.
Woody, G.E., Gallop, R., Luborsky, L., Blaine , J., Frank, A., Gastfriend, D., Crits-Christoph, P. and the Cocaine Psychotherapy Study Group. HIV risk reduction in the NIDA cocaine psychotherapy study. J. Acq. Immune Def. Syndromes. 33:82-87, 2003.
Woody, G.E. Research findings on psychotherapy of addictive disorders. Am. J. Addictions. 12 (suppl):S19-S26, 2003.
Rosenheck, R, Leslie, D, Woody, G. Fiscal strain and access to opiate substitution therapy at Department of Veterans Affairs Medical Centers. Am. J. Addictions 12:220-228, 2003.
Pechansky, F., von Diemen, L., Kessler, F., Hirakata, V., Metzger, D., Woody, G.E. Preliminary estimates of HIV prevalence and incidence among cocaine abusers of Porto Alegre, Brazil. J. Urban Health 80 (1): 115-26, 2003.
Woody, G.E., Senay, E.C., Geller, A., Adams, E.H., Inciardi, J.A., Schnoll, S., Muñoz, A., Cicero , T.J. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride). Drug and Alc. Dep. In press, 2003.
Woody, G.E., McNicholas, L.F. Putting Addiction Treatment Medications to Use: Lessons Learned. In: IOM report on immunotherapies and depot medications for treatment of addictive disorders. In press, 2003.
Woody, G.E., Luborsky, L., McLellan, A.T., O'Brien, C.P., Beck, A.T., Blaine , J., Herman, I. , Hole, A. Psychotherapy for opiate addicts: Does it help.? Archives of General Psychiatry. 40:639-645, 1983.
Woody, G.E., O'Brien, C.P. McLellan, A.T. Treatments for Opiate Dependence. Psychiatric Annals., 14(4): 257-263, 1984.
Woody, G.E., McLellan, A.T., Luborsky, L. O'Brien, C.P., Blaine , J., Fox, S., Herman, I. , Beck, A.T. Psychiatric Severity as a Predictor of Benefits from Psychotherapy: The Penn-VA Study. Am. J. Psych., 141:1172-1177, 1984.
Metzger, D.S., Woody, G.E., McLellan, A.T., Druley, P., DePhilippis, D., O'Brien, C.P., Stolley, P., Abrutyn, E. HIV conversion among in and out-of-treatment intravenous drug users in Philadelphia. J. of Acquir. Immune. Defic. Syndr. 6(9): 1049-1056, 1993.
Woody, G.E., McLellan, A.T., Luborsky, L., O'Brien, C.P. Psychotherapy in community methadone programs: A validation study. Am. J. Psychiatry, 152(9), 1302-1308,1995.
Woody, G.E., Donnell, D., Seage, G.R., Metzger, D., Marmor, M., Koblin, B.A., Buchbinder, S., Gross, M., Stone, B., Judson, F.N. Non-injection substance use correlates with risky sex among men having sex with men: data from HIVNET. Drug and Alc. Dep. 53:197-205, 1999.
